Termination by Xxxxxx Pursuant to Section 11. 2.1. If this Agreement is terminated by Xxxxxx pursuant to Section 11.2.1, the following provisions shall apply: (a) If Xxxxxx terminates the Agreement prior to the first anniversary of the first business day following the Approval Date, it shall make a [*****] time payment to Enanta of [*****] to complete the Upfront Fee as provided in Section 6.1; (b) the licenses granted to Xxxxxx pursuant to Sections 8.1.1 and 8.2.1 shall terminate upon the effective date of such termination; (c) Xxxxxx shall be deemed to have granted to Enanta, on and after the date of termination, (i) a non-exclusive, perpetual, fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Xxxxxx Program Technology and Xxxxxx Patent Rights and (ii) an exclusive (even as to Xxxxxx), perpetual, fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Xxxxxx’x interest in Joint Technology and Joint Patent Rights, in either case, to Develop and have Developed Candidates resulting from Compounds and Xxxxxx Compounds, other than Xxxxxx Compounds listed on Schedule 1, and Commercialize Products derived from such Candidates; (d) all exclusivity obligations of Enanta under Section 8.5.1 shall terminate upon the effective date of such termination and Enanta shall thereafter have the right to Develop Candidates and Commercialize Products for any and all uses within the Field; (e) each Party shall promptly return all Confidential Information of the other Party that is not subject to a continuing license hereunder; provided that each Party may retain one (1) copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder; (f) upon request of Enanta, Xxxxxx shall promptly, and in any event within sixty (60) days after Enanta’s request: (i) transfer to Enanta all right, title and interest in and to all Product Trademarks and registrations thereof, if any; (ii) transfer to Enanta all of its right, title and interest in all Regulatory Filings, Drug Approval Applications and Regulatory Approvals then in its name applicable to any Candidate or Product, and all material aspects of Confidential Information Controlled by it as of the date of termination relating to Regulatory Filings, Drug Approval Applications and Regulatory Approvals; provided that Enanta shall as of the date of such transfer, assume all obligations and liabilities associated with such Regulatory Filings, Drug Approval Applications and Regulatory Approvals; (iii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect such transfer; (iv) provide Enanta with copies of all correspondence between Xxxxxx and such Regulatory Authorities relating to such Regulatory Filings, Drug Approval Applications and Regulatory Approvals; (v) unless expressly prohibited by any Regulatory Authority, transfer control to Enanta of all clinical trials of any Candidate or Product being conducted as of the effective date of termination, and upon such transfer Enanta shall assume all obligations and liabilities associated with continuing such clinical trials; (vi) assign (or cause its Affiliates to assign) to Enanta all agreements with any Third Party with respect to the conduct of clinical trials for any Candidate or Product including, without limitation, agreements with contract research organizations, clinical sites and investigators, unless expressly prohibited by any such agreement (in which case Xxxxxx shall cooperate with Enanta in all reasonable respects to secure the consent of such Third Party to such assignment); (vii) provide Enanta with all supplies of any Candidate or Product in the possession of Xxxxxx or any Affiliate or contractor of Xxxxxx; and (viii) provide Enanta with copies of all reports and data generated or obtained by Xxxxxx or its Affiliates pursuant to this Agreement that relate to any Candidate or Product that has not previously been provided to Enanta; and (g) if Xxxxxx has manufactured, is manufacturing or having manufactured any Candidate or Product or any intermediate thereof as of the effective date of termination: (i) Xxxxxx shall, if requested by Enanta, supply Enanta with its requirements for all such Candidate or Product and intermediate for up to [*****] months following such termination [*****]; and (ii) within sixty (60) days after Enanta’s request, Xxxxxx shall provide to Enanta or its designee all information in its possession with respect to the manufacture of each such Candidate, Product or intermediate.
Appears in 4 contracts
Samples: Collaborative Development and License Agreement (Enanta Pharmaceuticals Inc), Collaborative Development and License Agreement (Enanta Pharmaceuticals Inc), Collaborative Development and License Agreement (Enanta Pharmaceuticals Inc)
Termination by Xxxxxx Pursuant to Section 11. 2.1. If this Agreement is terminated by Xxxxxx pursuant to Section 11.2.1, the following provisions shall apply:
(a) If Xxxxxx terminates the Agreement prior to the first anniversary of the first business day following the Approval Date, it shall make a [*****] time payment to Enanta of [*****] to complete the Upfront Fee as provided in Section 6.1;
(b) the licenses granted to Xxxxxx pursuant to Sections 8.1.1 and 8.2.1 shall terminate upon the effective date of such termination;
(c) Xxxxxx shall be deemed to have granted to Enanta, on and after the date of termination, (i) a non-exclusive, perpetual, fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Xxxxxx Program Technology and Xxxxxx Patent Rights and (ii) an exclusive (even as to Xxxxxx), perpetual, fully-paid, worldwide, royalty-free license, with the rights to sublicense, under Xxxxxx’x interest in Joint Technology and Joint Patent Rights, in either case, to Develop and have Developed Candidates resulting from Compounds and Xxxxxx Compounds, other than Xxxxxx Compounds listed on Schedule 1, and Commercialize Products derived from such Candidates;
(d) all exclusivity obligations of Enanta under Section 8.5.1 shall terminate upon the effective date of such termination and Enanta shall thereafter have the right to Develop Candidates and Commercialize Products for any and all uses within the Field;
(e) each Party shall promptly return all Confidential Information of the other Party that is not subject to a continuing license hereunder; provided that each Party may retain one (1) copy of the Confidential Information of the other Party in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder;
(f) upon request of Enanta, Xxxxxx shall promptly, and in any event within sixty (60) days after Enanta’s request: (i) transfer to Enanta all right, title and interest in and to all Product Trademarks and registrations thereof, if any; (ii) transfer to Enanta all of its right, title and interest in all Regulatory Filings, Drug Approval Applications and Regulatory Approvals then in its name applicable to any Candidate or Product, and all material aspects of Confidential Information Controlled by it as of the date of termination relating to Regulatory Filings, Drug Approval Applications and Regulatory Approvals; provided that Enanta shall as of the date of such transfer, assume all obligations and liabilities associated with such Regulatory Filings, Drug Approval Applications and Regulatory Approvals; (iii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect such transfer; (iv) provide Enanta with copies of all correspondence between Xxxxxx and such Regulatory Authorities relating to such Regulatory Filings, Drug Approval Applications and Regulatory Approvals; (v) unless expressly prohibited by any Regulatory Authority, transfer control to Enanta of all clinical trials of any Candidate or Product being conducted as of the effective date of termination, and upon such transfer Enanta shall assume all obligations and liabilities associated with continuing such clinical trials; (vi) assign (or cause its Affiliates to assign) to Enanta all agreements with any Third Party with respect to the conduct of clinical trials for any Candidate or Product including, without limitation, agreements with contract research organizations, clinical sites and investigators, unless expressly prohibited by any such agreement (in which case Xxxxxx shall cooperate with Enanta in all reasonable respects to secure the consent of such Third Party to such assignment); (vii) provide Enanta with all supplies of any Candidate or Product in the possession of Xxxxxx or any Affiliate or contractor of Xxxxxx; and (viii) provide Enanta with copies of all reports and data generated or obtained by Xxxxxx or its Affiliates pursuant to this Agreement that relate to any Candidate or Product that has not previously been provided to Enanta; and
(g) if Xxxxxx has manufactured, is manufacturing or having manufactured any Candidate or Product or any intermediate thereof as of the effective date of termination: (i) Xxxxxx shall, if requested by Enanta, supply Enanta with its requirements for all such Candidate or Product and intermediate for up to [*****] months following such termination [*****]; and (ii) within sixty (60) days after Enanta’s request, Xxxxxx shall provide to Enanta or its designee all information in its possession with respect to the manufacture of each such Candidate, Product or intermediate.;
Appears in 1 contract
Samples: Collaborative Development and License Agreement (Enanta Pharmaceuticals Inc)